PURPOSE: To report the outcome using radiation therapy (RT) for pediatric patients with high-grade spinal cord tumors. METHODS AND MATERIALS: A retrospective chart review was conducted that included 17 children with high-grade spinal cord tumors treated with RT at St. Jude Children's Research Hospital between 1981 and 2007. Three patients had gross total resection, 11 had subtotal resection, and 3 underwent biopsy. The tumor diagnosis was glioblastoma multiforme (n = 7), anaplastic astrocytoma (n = 8), or anaplastic oligodendroglioma (n = 2). Seven patients received craniospinal irradiation (34.2-48.6 Gy). The median dose to the primary site was 52.2 Gy (range, 38-66 Gy). RESULTS: The median progression-free and overall survivals were 10.8 and 13.8 months, respectively. Local tumor progression at 12 months (79% vs. 30%, p = 0.02) and median survival (13.1 vs. 27.2 months, p = 0.09) were worse for patients with glioblastoma multiforme compared with anaplastic astrocytoma or oligodendroglioma. The median overall survival was shorter for patients when failure included neuraxis dissemination (n = 8) compared with local failure alone (n = 5), 9.6 vs. 13.8 months, p = 0.08. Three long-term survivors with World Health Organization Grade III tumors were alive with follow-up, ranging from 88-239 months. CONCLUSIONS: High-grade spinal cord primary tumors in children have a poor prognosis. The propensity for neuraxis metastases as a component of progression after RT suggests the need for more aggressive therapy.
PURPOSE: To report the outcome using radiation therapy (RT) for pediatric patients with high-grade spinal cord tumors. METHODS AND MATERIALS: A retrospective chart review was conducted that included 17 children with high-grade spinal cord tumors treated with RT at St. Jude Children's Research Hospital between 1981 and 2007. Three patients had gross total resection, 11 had subtotal resection, and 3 underwent biopsy. The tumor diagnosis was glioblastoma multiforme (n = 7), anaplastic astrocytoma (n = 8), or anaplastic oligodendroglioma (n = 2). Seven patients received craniospinal irradiation (34.2-48.6 Gy). The median dose to the primary site was 52.2 Gy (range, 38-66 Gy). RESULTS: The median progression-free and overall survivals were 10.8 and 13.8 months, respectively. Local tumor progression at 12 months (79% vs. 30%, p = 0.02) and median survival (13.1 vs. 27.2 months, p = 0.09) were worse for patients with glioblastoma multiforme compared with anaplastic astrocytoma or oligodendroglioma. The median overall survival was shorter for patients when failure included neuraxis dissemination (n = 8) compared with local failure alone (n = 5), 9.6 vs. 13.8 months, p = 0.08. Three long-term survivors with World Health Organization Grade III tumors were alive with follow-up, ranging from 88-239 months. CONCLUSIONS: High-grade spinal cord primary tumors in children have a poor prognosis. The propensity for neuraxis metastases as a component of progression after RT suggests the need for more aggressive therapy.
Authors: Kenneth C Loh; Jennifer Willert; Hal Meltzer; William Roberts; Bryce Kerlin; Richard Kadota; Michael Levy; Greg White; Amy Geddis; Deborah Schiff; Laura Martin; Alice Yu; Faith Kung; Matthew A Spear Journal: J Pediatr Hematol Oncol Date: 2005-05 Impact factor: 1.289
Authors: M P McLaughlin; R B Marcus; J M Buatti; W M McCollough; J P Mickle; A Kedar; B L Maria; R R Million Journal: Int J Radiat Oncol Biol Phys Date: 1998-03-01 Impact factor: 7.038
Authors: N J Laperriere; P M Leung; S McKenzie; M Milosevic; S Wong; J Glen; M Pintilie; M Bernstein Journal: Int J Radiat Oncol Biol Phys Date: 1998-07-15 Impact factor: 7.038
Authors: Robert G Selker; William R Shapiro; Peter Burger; Margaret S Blackwood; Vincent C Arena; John C Gilder; Mark G Malkin; John J Mealey; John H Neal; Jeffrey Olson; James T Robertson; Gene H Barnett; Stephen Bloomfield; Robert Albright; Fred H Hochberg; Emile Hiesiger; Sylvan Green Journal: Neurosurgery Date: 2002-08 Impact factor: 4.654
Authors: Zachary D Guss; Shalini Moningi; George I Jallo; Kenneth J Cohen; Moody D Wharam; Stephanie A Terezakis Journal: Int J Radiat Oncol Biol Phys Date: 2013-02-20 Impact factor: 7.038
Authors: Hadie Adams; Javier Avendaño; Shaan M Raza; Ziya L Gokaslan; George I Jallo; Alfredo Quiñones-Hinojosa Journal: Spine (Phila Pa 1976) Date: 2012-05-20 Impact factor: 3.468
Authors: Muhammad M Abd-El-Barr; Kevin T Huang; Ziev B Moses; J Bryan Iorgulescu; John H Chi Journal: Neuro Oncol Date: 2018-05-18 Impact factor: 12.300
Authors: Robert Lober; Suash Sharma; Beverly Bell; Alan Free; Ramon Figueroa; Chris W Sheils; Mark Lee; John Cowell Journal: Rare Tumors Date: 2010-09-30
Authors: Philip J O'Halloran; Michael Farrell; John Caird; Michael Capra; David O'Brien Journal: Childs Nerv Syst Date: 2013-01-15 Impact factor: 1.475
Authors: Sophie Pietschmann; André O von Bueren; Guido Henke; Michael Josef Kerber; Rolf-Dieter Kortmann; Klaus Müller Journal: J Neurooncol Date: 2014-08-27 Impact factor: 4.130
Authors: Sophie Pietschmann; André O von Bueren; Michael J Kerber; Brigitta G Baumert; Rolf Dieter Kortmann; Klaus Müller Journal: PLoS One Date: 2015-04-10 Impact factor: 3.240
Authors: Jae Ho Kim; Sang Kwang Lee; Yong Cheol Yoo; Nam Hyun Park; Dan Bi Park; Jong Shin Yoo; Hyun Joo An; Young Mok Park; Kyung Gi Cho Journal: Med Sci Monit Date: 2012-11